QS Investors’s AC Immune ACIU Stock Holding History

QS Investors’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-123,651	Closed	-$854K	–	1641
2020 Q1	$854K	Buy	+123,651	New	+$966K	0.01%	707

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

QS Investors's ACIU Position: Q2 2020 in Review

QS Investors sold out of AC Immune (ACIU) in Q2 2020, closing a stake of 123,651 shares — an estimated $854K sold.

QS Investors first reported a position in ACIU in Q1 2020 and held it in 1 quarter. The position peaked at $854K in Q1 2020. 42 funds tracked by Wall St. Rank hold ACIU as of Q2 2020.

QS Investors reported no remaining AC Immune position as of Q2 2020 after selling out during the quarter.
QS Investors sold 123,651 AC Immune shares in Q2 2020, an estimated $854K.
QS Investors first reported a position in AC Immune in Q1 2020 and held it in 1 quarter.
QS Investors's AC Immune position peaked at $854K in Q1 2020.
42 funds tracked by Wall St. Rank held AC Immune as of Q2 2020.

Based on QS Investors's 13F filing for Q2 2020, filed 14 Aug 2020.